Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement

Core Points - Ventripoint Diagnostics Ltd. announced the issuance of an additional $297,000 of unsecured convertible debenture units, bringing the total to $567,000 for the Offering [1][2] - Each unit consists of a $1,000 unsecured convertible debenture and 9,000 common share purchase warrants [1] - The conversion price for the debentures is set at $0.11 per common share, with warrants exercisable at $0.14 until December 31, 2027 [2] Financial Details - The debentures mature on December 31, 2027, and carry a 10% interest rate, payable semi-annually [3] - The Corporation paid a total of $320 in cash finder's fees and issued 2,286 finder's warrants, which can be exercised at $0.11 per share for 18 months [4] - Proceeds from the Offering will be used for operational costs, sales and marketing, and general working capital [5] Regulatory and Market Information - All securities issued are subject to a four-month hold period and require approval from the TSXV [6] - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be sold in the U.S. without proper registration or exemption [7] Company Overview - Ventripoint is a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI [8] - The technology is versatile and compatible with all ultrasound systems, supported by regulatory approvals in the U.S., Europe, and Canada [9]